Results for ''
EMPA-KIDNEY is an international clinical trial by Oxford Population Health scientists in collaboration with academics spanning eight countries. The study recruited over 6000 participants to...
A large-scale clinical trial of a monoclonal antibody treatment for COVID-19 showed that it could reduce deaths by 21 per cent in people who had not mounted a natural antibody response of their own.
Linking historic trial data with electronic health records allowed this dormant trial on the relationship between infant formula and cognitive ability to become reactivated - making it the first...
Overview Patient Reported Outcomes (PROs) can provide valuable evidence on the impact of disease and treatment on patients’ symptoms, function and quality of life. High-quality PRO data from...
Overview Blood cancer diagnosis and classification is highly complex, presenting major challenges for clinicians working in pressured environments. The creation of a decision tree application...
Overview The paper describes high-quality research into the development of a new approach for deriving patient phenotype profiles using clinical narrative texts. Its aim was to find ways to use...
HDR UK's Matt Sydes and colleagues have identified several barriers to overcome such that routinely collected health care data can better support randomised clinical trials.
The RECOVERY Trial has been set up in record time to test drugs against COVID-19 and findings thus far have informed policy and saved lives.
The first systematic review of randomised controlled trials using routine health data from UK-based data registries suggests there may be multiple barriers to using registry data.